Volume 34, No 8, Aug 2024

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 34 Issue 8, August 2024: 541-542

RESEARCH HIGHLIGHTS

Prometheus 2.0: drug-induced liver regeneration arising

Jan S. Tchorz^*

Biomedical Research, Novartis Pharma AG, Basel, Switzerland
Correspondence: Jan S. Tchorz(jan.tchorz@novartis.com)

In a recent publication in Cell, a multidisciplinary academic drug discovery team, with its spin-off HepaRegeniX, published a first-in-class small molecule MKK4 inhibitor (HRX215) with remarkable efficacy in multiple preclinical liver regeneration models and positive first-in-human data. Its potential to prevent liver failure and boost regeneration may provide a novel therapeutic avenue for many patients with liver disease.

https://doi.org/10.1038/s41422-024-00965-w

FULL TEXT | PDF

Browse 358